D-Rev's 2014 Annual Report

2. 2 D-Rev Annual Report D-Rev Annual Report 3
Our Mission
D-Rev exists to close the quality healthcare
gap for under-served populations by
designing and delivering user-centric medical
technologies. Human potential relies on good
health. We are committed to improving health
for all people, regardless of their income or
place of birth.
It is our goal that D-Rev products will treat
millions of people.
It is our hope that our work will catalyze
global change to make world-class healthcare
accessible for all.
D-Rev Annual Report 3

3. D-Rev Annual Report 5
Table of Contents
06 Newborn Health
18 Mobility
24 Impact
30 Research & Development
34 Support
4 D-Rev Annual Report
Dear Friends,
Just five years ago our team of three was cramped
in our first office in a grey Victorian house off of
University Avenue in Palo Alto. We were drowning
in design work and prototypes and struggling to
increase the impact of our products while remaining
financially sustainable. This year we launched our
second product to market, Brilliance Pro, and have
invested hours with far-flung partners who will help
us deliver the ReMotion Knee to amputees all over
the world.
We are moving into 2015 positioned for growth. We have narrowed our organizational focus to
work exclusively on products that improve health, and by the end of the year we will have four
products on the market. With a strong track record of not just designing—but also delivering via
the market—products to patients who need them most, we are thinking about our next projects.
In the coming year we will refine and define what research and development means to D-Rev.
We celebrate our successes in scaling current projects, while being mindful about how our
challenges will inform future product development.
At D-Rev we value curiosity, fearlessness, and pragmatism in our approach to problem solving.
And we believe our accomplishments and lessons learned in 2014 will change the way healthcare
is delivered.
In 2014:
• D-Rev’s products entered 10 new countries, scaling organically via the market
• Brilliance Classic sales grew 70% year-over-year, scaling faster than we had ever anticipated
(with major kudos to our partner Phoenix Medical Systems)
• We discontinued our work on Comet, but it better informed other work that we believe will
lead to greater impact (see more in our newborn health section!)
• We launched our impact dashboards making our impact, data, assumptions, and calculations
public and transparent
This progress would not be possible without you, our supporters, partners, families, and friends
who have allowed us to create and scale our impact. We are so very grateful. Because of you we
have made meaningful progress to close the gap for those who previously have been unable to
access existing healthcare—making world-class a global standard.
Thank you,
Krista Donaldson
CEO, D-Rev

4. D-Rev Annual Report 76 D-Rev Annual Report
Newborn
Health
Dr. Vijay Raj, head doctor in a government
hospital outside of Chennai. The hospital
currently has four Brilliance units installed.

5. 8 D-Rev Annual Report D-Rev Annual Report 9
Overview
D-Rev’s Newborn Health project aims to
provide world-class, affordable phototherapy
devices to treat the millions of newborns at risk
for adverse effects of severe jaundice, like brain
damage or death.
By the end of 2014, D-Rev’s Brilliance devices have cumulatively treated over 47,000
babies, with almost 35,000 of those in 2014 alone. Brilliance has saved over 600
babies, over 450 in 2014, from disability or death as a result of one of the most
common newborn conditions, newborn jaundice.
In 2015 it is our goal to accelerate sales of
Brilliance Classic and Brilliance Pro, particularly
in high need regions of India. We will do this
by supporting business development activities
and working on the ground with our sales and
distribution partners.
See our full Newborn
Health impact dashboard
at D-Rev.org/impact
Newborn Health 9
Lesson Learned
When we set out to make Brilliance Pro we strove to make
a high-performance, affordable device that incorporated
additional features that clinicians were demanding.
Along the way we improved the look and feel of the
device as well—a sleeker profile, a clearer display, and a
more convenient tilting mechanism. It turned out these
aesthetic improvements had a profound impact on how
the product was perceived.
Doctors seeing Brilliance Pro at launch events in India
wanted to own a device that worked well and looked
good. Expectations of customers in every market are
rising. Product designers must account for aesthetic
alongside other core functionality when designing for
low-resource markets.

6. 10 D-Rev Annual Report
BEST IN
SHOW
NEOCON 2014
Read more: WIRED + FAST COMPANY
Brilliance Pro
We anticipate that our newest product,
Brilliance Pro, which launched December 2014,
will accelerate our impact.
Brilliance Pro offers a streamlined design, improved design for manufacturability,
and patent-pending SmartTilt technology to ensure effective treatment when used
with other equipment in the NICU. In addition to these features, Brilliance Pro can
include the Brilliance Pro Light Meter—an optional accessory that enables clinicians
to verify effective treatment—the first time such a device has been available to
clinicians at an affordable price. Reflecting D-Rev’s commitment to exceeding
user-expectations in its designs, Brilliance Pro won Best in Show at NEOCON
2014, India’s largest conference for neonatal care, beating out multi-national
corporation’s devices across all product categories and price points.
INTRODUCING: The Brilliance Pro Light
Meter was previously
known as Bullseye!
Doctors and neonatologists, with
project manager AJ Viola, around
Brilliance Pro at the launch event
in Chennai, hosted by Phoenix
Medical Systems.

7. 12 D-Rev Annual Report
Dr. S. Kumar, a
neonatologist at a
government hospital
outside of Chennai, holding
the Bhutani Nomogram.
The Bhutani Nomogram
is the global standard for
indicating when babies
should be treated with
jaundice. Dr. Vinod Bhutani,
creator of the nomogram,
is a D-Rev Advisor to the
Newborn Health project.
Newborn Health 13
34,905
Babies Treated
29,233
Babies Otherwise
454
Deaths & Disabilities Averted
445
Units Installed
2014 Impact: Newborn Health
43,000 to-date
by end of
2014
326% growth
since our 2013
Annual Report
learn more on
page 27!
babies treated
who would
not otherwise
have received
effective
treatment
Read our step-by-step guide to calculating Brilliance impact #s

8. D-Rev Annual Report 15
Product Development
In 2014, additional projects in the Newborn
Health project area emerged based on user’s
needs and were developed to complement
the Brilliance product line, address existing
barriers to effective treatment, or expand
market share.
In 2014 we worked on three new products in the Newborn Health project area:
Bullseye, Comet, and Brilliance Pro Shippable. They are intended to complement
the Brilliance product line, expand market share, or address existing barriers to
effective treatment.
Product Manager Garrett
Spiegel working on design
requirements for Comet.
Brilliance Pro Light Meter
A tool for doctors & nurses to measure
the wavelength of light from Brilliance,
ensuring effective treatment.
GOAL RELEASE | 2014
ACTUAL RELEASE | 2015
LESSON LEARNED | Doctors and nurses use light meters to ensure
phototherapy treatment is being delivered effectively. Because of their
exorbitant cost light meters are uncommon in India and other low-
resource regions. While the Brilliance Pro Light Meter is an accessory
product used exclusively with the Brilliance Pro phototherapy unit,
product development and manufacturing of the device required a
substantial amount of learning and iterating. D-Rev needed to ensure
it had extensive skill and knowledge to produce a high quality product,
including purchasing additional equipment and validating design
specifications through third-party testing.
Newborn Health 15
aka Bullseye!

9. D-Rev Annual Report 1716 D-Rev Annual Report
Comet
Rural phototherapy treatment for babies
far from urban referral centers.
GOAL RELEASE | 2014
ACTUAL RELEASE | Discontinued
LESSON LEARNED | After field testing in three countries, we
concluded that introducing phototherapy to rural clinics and
hospitals will not have measurable impact and could, in fact, have
negative consequences.
Most rural clinics did not keep babies overnight, or did not have the
capacity for inpatient care. Phototherapy requires uninterrupted
treatment for 2-4 days. Also, we observed that comorbidities were
often present, requiring additional treatment for other very serious
issues like hypothermia, and phototherapy wouldn’t be successful
without additional devices like warmers.
Comet was not a failure. In design, everything is information for
the next iteration. User testing for Comet focused our attention
on areas to improve upon in the distribution and supply chain of
Brilliance.
Read our detailed blog post about our learnings from Comet
Newborn Health 17
Brilliance Pro Shippable
Even more affordable treatment for
hospitals and clinics outside of India.
GOAL RELEASE | 2016
LESSON LEARNED | Our theory of change for Comet was that
expanding access of effective phototherapy to rural clinics was the
most sizable way for us to grow our impact. As part of our field
testing of Comet we learned that barriers exist to distribution and
scaling outside of India that have little to do with product features
or differing user needs. Transportation cost is a not insignificant
component of overall cost and we believe by thinking smarter about
the overall design of the product we can have significant impact on
end-pricing, making the product more accessible to high need parts
of the world.

10. 18 D-Rev Annual Report D-Rev Annual Report 1918 D-Rev Annual Report
Mobility
ReMotion Knee product manager Vinesh
Narayan making adjustments to a patient’s
ReMotion Knee at the JaipurFoot Organization
in Jaipur, India.

11. 20 D-Rev Annual Report D-Rev Annual Report 21
Overview
D-Rev’s Mobility project aims to equalize
access to high quality mobility devices.
We’re incredibly proud of the work that has been done by the ReMotion Knee
team this year. We completed field trials of the ReMotion Knee in four clinical
sites in Guatemala, India, and Indonesia, allowing us to finalize the design and
begin working with a contract manufacturer to mass produce the product. This
is a critical milestone in the history of the ReMotion Knee. As a result of years of
work the ReMotion Knee will finally be available for public sale in 2015, and as
forecasted the retail price will remain at or below $80 USD.
D-Rev will focus exclusively on launching the
ReMotion Knee in India, followed soon by two
additional high-need countries.
Mobility 21
Lesson Learned
Continuously remind partners that all feedback is
good feedback. One of our most valuable partners,
a clinic in Indonesia, was hesitant to report back
on ReMotion problems during field tests. It took
the D-Rev team some time to convince them that
it was the most valuable information they could
provide and, when delivered, their detailed notes
and observations turned out to be crucial in the
development of the ReMotion Knee. Without
their honesty we would have missed key learning
opportunities in the product’s development.

12. 22 D-Rev Annual Report Mobility Impact Dashboard: www.d-rev.org/impact—cumulative numbers available
6,632
Total number of amputees
fit by end of 2014
1,194
Amputees fit with the
JaipurKnee in 2014 at the
JaipurFoot Organization
in Jaipur, India
52
Amputees fit with the
ReMotion Knee in 2014
2014 Impact: Mobility
29% growth since our
2013 Annual Report
Product Development
2015 will be a year of enormous growth for
the ReMotion team.
Not only will we launch the ReMotion Knee to market mid-year, but we will also
start on the next mobility product. We are always on the look out for new ideas
that will complement our existing products.
Stay tuned for further updates later this year.
Senior R&D Engineer Michael Hong
working with the ReMotion Knee’s
manufacturer in China.

13. 24 D-Rev Annual Report D-Rev Annual Report 2524 D-Rev Annual Report
Impact
Brilliance Classic treats a baby girl in a
government hospital outside of Chennai.
D-Rev estimates that over 220 babies were
treated by this hospital in 2014.

14. 26 D-Rev Annual Report D-Rev Annual Report 27
Overview
D-Rev’s impact assessment aims to
understand the results and effectiveness of
our products, as well as inform our future
product development.
In 2014, we worked constantly to integrate impact assessment cross-functionally,
and earlier across all our teams. We now approach impact with a “first in, last out”
mentality—considering impact at the inception of a product and measuring long
after D-Rev engineering activities cease.
This year D-Rev will launch long-term impact
assessment for the ReMotion Knee, increase
the amount of data collected on Brilliance,
and initiate third-party evaluations of both
products. In addition, it is a priority to establish
organization-wide impact assessment,
especially as we evaluate new projects and
areas for growth at D-Rev.
every company needs to have
a dashboard like [D-Rev's]
integrated into decision-making
Nathan Shedroff,
Design Museum UNITE
on Impact Design event
Impact 27
Lesson Learned
When estimating impact we differentiate between
the sales and installation or fitting of a device, and
only report impact from devices we know are in
use. In 2014 we learned that there are particularly
challenging aspects to gathering data about devices
sold outside of India.
By the end of 2014 over 1,200 Brilliance devices
had been sold to over 20 countries. We only
reported confirmed installations of 777 devices
installed in nine countries. We estimate our impact
may be as much as 25% higher than what we
publicly report for Brilliance.
While we are working actively in 2015 to address
these challenges, we remain committed to full
transparency and consistency in our reporting, only
publishing impact numbers for devices we know are
in use and treating patients.

15. Impact Dashboards
The pursuit of ever greater impact inspires our
work and pushes us to continually improve
our methods for collecting, analyzing, and
reporting not just the direct impact of our
products, but also our indirect impact on the
industries in which we operate.
We are driven by the notion that everyone deserves good design and our work
will be done when under-served populations around the world have access to the
healthcare they need whether by our products or not.
August 2014 (V2)June 2014 (V1)
we added data visualizations!
DONATE PRODUCTS IMPACT BLOG MEDIA ABOUT
255babies treated
with Brilliance
4newborn deaths and
disabilities averted
22babies treated who
otherwise would not have
received effective treatment
ReMotion Brilliance
4,678
patients have been
fit with ReMotion’s
Jaipur Knee
79%
of these patients are still
wearing their prostheses
95%
of patients report no
failures in their JaipurKnees
Baby Hope
Baby Hope was the first baby treated with Brilliance. Born prematurely
in 2010 at less than 3 lbs, Baby Hope was diagnosed with jaundice.
Lab results showed that his jaundice was so severe that he needed a
blood transfusion. Fearing that the baby would not survive the
transfusion, his pediatrician decided to use phototherapy instead.
View full dashboard Quick look View full dashboard Quick look
DONATE PRODUCTS IMPACT BLOG MEDIA ABOUT
255babies treated
with Brilliance
4newborn deaths and
disabilities averted
22babies treated who
otherwise would not have
received effective treatment
ReMotion Brilliance
4,678
patients have been
fit with ReMotion’s
Jaipur Knee
79%
of these patients are still
wearing their prostheses
95%
of patients report no
failures in their JaipurKnees
Baby Hope
Baby Hope was the first baby treated with Brilliance. Born prematurely
in 2010 at less than 3 lbs, Baby Hope was diagnosed with jaundice.
Lab results showed that his jaundice was so severe that he needed a
blood transfusion. Fearing that the baby would not survive the
transfusion, his pediatrician decided to use phototherapy instead.
Baby Hope
Baby Hope was the first baby treated with
Brilliance. Born prematurely in 2010 at less
than 3 lbs, Baby Hope was diagnosed with
View full dashboard Quick look View full dashboard Quick look
enter your email for D-Rev news
CONNECT
+1 (415) 642-1143
info@d-rev.org
ABOUT US
our blog
press releases
PRODUCTS
ReMotion
Brilliance
GET INVOLVED
donate
opportunities
received effective treatmentJaipur Knee
Social impact drives everything we do at D-Rev. In order to know that we are making the impact we intend, we
strive to measure not just the number of products we sell, but how many people actually use and benefit from the
product, and how we can do better. Tracking impact isn’t cheap, but it’s essential to keeping us focused on our
goals, accountable to our donors and users, and constantly learning how to do better.
What drives our impact assessment?
A commitment to transparency, accountability, and learning.
Baby Hope
Baby Hope was the first baby treated with Brilliance.
Born prematurely in 2010 at less than 3 lbs, Baby Hope
was diagnosed with jaundice. Lab results showed that
his jaundice was so severe that he needed a blood
transfusion.
Baby Hope
Baby Hope was the first baby treated with
Brilliance. Born prematurely in 2010 at less
than 3 lbs, Baby Hope was diagnosed with
jaundice. Lab results showed that his jaundice
was so severe that he needed a blood
transfusion. Fearing that the baby would not
survive the transfusion, his pediatrician decided
to use phototherapy instead.
View full dashboard Quick look View full dashboard Quick look
September 2014
we
added
user
stories
in V3

16. D-Rev Annual Report 3130 D-Rev Annual Report
Research &
Development
Senior R&D Engineer Michael Hong working
on quality assurance processes with the
ReMotion manufacturer.

17. 32 D-Rev Annual Report
Overview
D-Rev’s approach to R&D continues to evolve.
As we grow; we aim to formalize and refine
our process for selecting projects so that we
maximize the future impact of the organization.
LESSON LEARNED | Involve manufacturing partners early and often in the design
process. Doing so saves on re-work and increases the likelihood of getting a high-
quality product to market in a timely fashion. While this seems like common sense
to many of us, there is often an inclination to go to manufacturers with a finished or
nearly finished design.
In the upcoming year, D-Rev will establish a new
group to manage R&D processes and tools, and
new project selection. We will build a foundation
for D-Rev’s growth in the coming years—and
will soon select D-Rev’s next project.
Identify Design
next? stay tuned!
Research & Development 33
Deliver
Scale
Measure
Brilliance
Classic
Brilliance Pro
ReMotion Knee
Brilliance Pro
Light meter
Brilliance Pro
Shippable

18. D-Rev Annual Report 3534 D-Rev Annual Report
Support
Devi, a young mother in
Tamil Nadu, whose daughter
was just treated by Brilliance
for four days, after a failed
treatment in a CFL device.

19. 36 D-Rev Annual Report D-Rev Annual Report 37
2014 Financials
2014 REVENUE BY
SOURCE
2014 EXPENSES BY
PROGRAM
2014 EXPENSES
ALLOCATION
35%
44%
78%
14%
8%
30%
14%
8%
25%
22%
1% 1%*3%
17%
Program
Administration
Development
Foundations
Bilateral
Individuals
Corporate
Earned Income
Newborn Health
Mobility
General &
Administrative
Development
Impact
R&D*
* In the 2013 Annual Report we estimated 14% in R&D for 2014—we redefined R&D at D-Rev, separating it from
standard product development within our already defined project areas. Products previously categorized as R&D
(Bullseye, Comet) are now allocated under Newborn Health.
Support 37
S. Hussein wearing the ReMotion Knee at
the JaipurFoot Organization in Jaipur, India.
He is currently a university student, and
volunteering at an NGO.

20. 38 D-Rev Annual Report
Our Partners
ACADEMIC PARTNERS
CORPORATE PARTNERS
DESIGN PARTNERS
DELIVERY PARTNERS
THANK YOU!
You make everything possible.
Support 39
FINANCIAL SUPPORTERS
IN-KIND SUPPORTERS

21. 40 D-Rev Annual Report
Our Board of Directors
JOHN DAWSON
chairman of the
board
OLANA KHAN
STUART COULSON
treasurer
JAMES PATELLELLEN LEANSE
JENN BUECHEL
BILL UNGER
STEPHANIE DODSON
Support 41
KELLY BLANK
graphic designer
VINESH NARAYAN
ReMotion product
manager
SARA TOLLEFSON
director of impact
KRISTA DONALDSON
CEO
NICOLE RAPPIN
operations manager
ARUN VENKATESAN *
country manager, India
JESSE HAMLIN *
director of
communications
GARRETT SPIEGEL
product manager
AJ VIOLA
newborn health
project manager
MICHAEL HONG
senior R&D engineer
DINA TO *
donor relations
manager
ROBERT WEISS
business development
analyst
* a few new faces this year!Our Staff

22. THANK YOU!
Your support makes this possible.
© 2015 D-Rev All Rights Reserved
695 Minnesota Street, San Francisco, CA 94017
415-642-1143 / www.d-rev.org
D-Rev is a 501(c)3 non-profit organization